The unmet need
Cystic Fibrosis (CF) is an inherited, life-limiting disease affecting over 10,900 people in the UK.
People with CF experience a build-up of thick sticky mucus in the lungs, digestive system and other organs, causing a wide range of challenging symptoms affecting the entire body. In the lungs, bacteria get trapped in thick sticky mucus and are difficult to clear.

Antibiotics are routinely used to manage these infections which can be persistent. Over time and due to resistance, recurrent infections become difficult to treat which subsequently leads to irreversible lung damage.
Antimicrobials are vital to managing acute infections, known as exacerbations, and to help suppress or manage long-term chronic infections. Without these treatments, lung function and overall health, quality of life and life span of people living with CF are dramatically altered.

The discovery and development of new antimicrobials to treat infections associated with CF are, undoubtedly, an urgent unmet need.

The CF AMR Syndicate has been set up to accelerate the translation of CF antimicrobials to the clinic to bring new and effective treatment options to people with CF.
Our research agenda has been informed by extensive efforts to understand the research landscape and the needs of the CF infection research community. We have developed the agenda through a cross-sector collaborative approach, which has involved close working with people with CF.

To accelerate CF antimicrobial drug discovery & development, we are…
Creating resources for CF antimicrobial discovery and development.
The UK CF Infection Biorepository enables access to high-quality samples and data, including CF-relevant strains and isolates.
The patient-focussed Target Product Profiles (TPPs) for CF-related infections provide guidance in CF antimicrobial discovery and development to innovators in industry and academia.
Building a CF AMR network to facilitate collaboration and enable knowledge exchange.
Nurturing and supporting promising CF antimicrobial projects through dedicated support at Medicines Discovery Catapult, the Cystic Fibrosis Trust and LifeArc.
Our History
Contact CF AMR Syndicate
Have a question you can’t find the answer to or would like further information?
Thinking of joining our network?
Become part of a collaborative community that is working together to accelerate the development of CF antimicrobials and bring new treatments to people with CF.